Jefferies Financial Group Comments on Tilray Inc’s Q4 2022 Earnings (NASDAQ:TLRY)

Tilray Inc (NASDAQ:TLRYGet Rating) – Equities research analysts at Jefferies Financial Group dropped their Q4 2022 earnings per share (EPS) estimates for Tilray in a research note issued on Tuesday, July 26th. Jefferies Financial Group analyst O. Bennett now expects that the company will earn ($0.07) per share for the quarter, down from their previous estimate of ($0.05). The consensus estimate for Tilray’s current full-year earnings is ($0.17) per share.

Several other equities research analysts also recently weighed in on the company. Barclays reduced their price target on Tilray from $8.50 to $4.50 and set an “underweight” rating on the stock in a report on Wednesday, April 20th. Roth Capital reduced their price objective on Tilray from $8.00 to $4.00 and set a “neutral” rating on the stock in a report on Friday, July 15th. Piper Sandler reduced their price objective on Tilray from $6.00 to $3.00 and set a “neutral” rating on the stock in a report on Wednesday, June 15th. Cantor Fitzgerald restated a “neutral” rating and set a $5.75 price objective (down from $6.15) on shares of Tilray in a report on Friday, June 24th. Finally, Canaccord Genuity Group reduced their price objective on Tilray from $9.00 to $7.00 in a report on Wednesday, June 15th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $7.34.

Tilray Trading Up 12.0 %

Shares of NASDAQ TLRY opened at $3.65 on Thursday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.50 and a current ratio of 2.46. The business’s 50 day moving average price is $3.65 and its 200-day moving average price is $5.15. Tilray has a fifty-two week low of $3.00 and a fifty-two week high of $16.67. The company has a market cap of $1.82 billion, a price-to-earnings ratio of 19.21 and a beta of 2.60.

Insider Buying and Selling at Tilray

In other Tilray news, Director Brendan Kennedy sold 350,000 shares of the stock in a transaction on Tuesday, July 5th. The stock was sold at an average price of $3.09, for a total transaction of $1,081,500.00. Following the sale, the director now owns 7,624,196 shares of the company’s stock, valued at approximately $23,558,765.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 2.96% of the company’s stock.

Institutional Trading of Tilray

Institutional investors have recently made changes to their positions in the business. Confluence Wealth Services Inc. acquired a new stake in shares of Tilray in the 4th quarter worth $30,000. Dupont Capital Management Corp acquired a new stake in shares of Tilray in the 4th quarter worth $34,000. Farmers & Merchants Trust Co of Chambersburg PA boosted its position in shares of Tilray by 320.0% in the 1st quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 5,250 shares of the company’s stock worth $41,000 after purchasing an additional 4,000 shares in the last quarter. Prospera Financial Services Inc acquired a new stake in shares of Tilray in the 1st quarter worth $54,000. Finally, Toronto Dominion Bank boosted its position in shares of Tilray by 57.1% in the 1st quarter. Toronto Dominion Bank now owns 7,692 shares of the company’s stock worth $60,000 after purchasing an additional 2,795 shares in the last quarter. Institutional investors and hedge funds own 13.84% of the company’s stock.

Tilray Company Profile

(Get Rating)

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.

See Also

Earnings History and Estimates for Tilray (NASDAQ:TLRY)

Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.